Eric P. Winer MD

PubMed

• 2 citations
  Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/...
  Nadine Tung, Fengmin Zhao, Angela DeMichele, Aleix Prat, Eric P Winer
  Journal of Clinical Oncology. 2026-10-20
• Paxalisib with Trastuzumab for HER2-Positive Metastatic Breast Cancer with Active Brain Metastases: A Phase II Trial with Integrated Plasma and CSF ctDNA Analyses.
  Elia Segui, Jorge Gomez Tejeda Zañudo, Noah Graham, Patrick T Kurnia, Andrea N Perry
  Cancer Research Communications. 2026-10-19
• A randomized phase II study of fulvestrant with or without ganetespib in patients with endocrine resistant metastatic breast cancer.
  Albert Grinshpun, Adrienne G Waks, Jingxin Fu, Patrick Kurnia, Hao Guo
  The Oncologist. 2026-10-14

Journal Articles

• Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer  
  Eric P Winer, Louise C Walter, Mina S Sedrak, Tanya M Wildes, Stuart M Lichtman, Kathryn J Ruddy, JAMA Oncology
• Effect of Eribulin with or Without Pembrolizumab on Progression-Free Survival for Patients with Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer  
  Sara M Tolaney, Gerburg Wulf, Laura Spring, Beth Overmoyer, Ann H Partridge, Eric P Winer, JAMA Oncology
• Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase II KEYNOTE-086 Study  
  M C Liu, R Nanda, H S Rugo, E P Winer, S Adams, Annals of Oncology

Lectures

• Breast Cancer, New Horizons, Current Controversies 
  Harvard Medical School, Boston, Massachusetts - 7/11/2013
• 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium(SABCS) 
  UT Health Science Center San Antonio, San Antonio, Texas - 12/4/2012
• Breast Cancer, New Horizons, Current Controversies 
  Harvard Medical School, Boston, Massachusetts - 7/12/2012